Catherine Faircloth, NP
Nephrology · Macon, GANPI 1386320349
Payments from drug & device makers
Across 103 payments — averaging $26.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$523
- Aurinia Pharma U.S., Inc.$414
- Otsuka America Pharmaceutical, Inc.$335
- Ardelyx, Inc.$215
- Travere Therapeutics, Inc.$208
- Vifor Pharma, Inc.$206
- plus $792 from 15 others
What the payments were for
- Food & beverage$2,64798%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 16 | $523 |
| Aurinia Pharma U.S., Inc. | 17 | $414 |
| Otsuka America Pharmaceutical, Inc. | 12 | $335 |
| Ardelyx, Inc. | 5 | $215 |
| Travere Therapeutics, Inc. | 12 | $208 |
| Vifor Pharma, Inc. | 10 | $206 |
| Mallinckrodt Hospital Products Inc. | 4 | $131 |
| Daiichi Sankyo Inc. | 5 | $130 |
| Scpharmaceuticals Inc. | 1 | $110 |
| Bayer | 6 | $110 |
| Akebia Therapeutics Inc | 2 | $50 |
| Amgen | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Fresenius USA Marketing, Inc. | 2 | $31 |
| EMD Serono, Inc. | 1 | $28 |
| Novo Nordisk | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Novartis | 1 | $20 |
| Fresenius USA Manufacturing, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUPKYNIS$247
- XPHOZAH 30 MG$148
- FARXIGA$124
- FUROSCIX$110
How this compares
$2,693 in reported general payments places this provider in the 55th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Chloride | 41 | $967 |
| Bumetanide | 25 | $650 |
| Nifedipine ErNifedipine | 26 | $544 |
| Losartan Potassium | 47 | $395 |
| Amlodipine Besylate | 112 | $389 |
| Cefdinir | 21 | $326 |
| Hydralazine Hcl | 23 | $306 |
| Furosemide | 68 | $274 |
| Allopurinol | 37 | $262 |
| Carvedilol | 49 | $259 |
| Amiloride Hcl | 19 | $202 |
| Hydrochlorothiazide | 15 | $166 |
| Spironolactone | 38 | $166 |
| Metoprolol Succinate | 14 | $123 |
| Lisinopril | 21 | $78 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Macon
- Sagar PanseMacon$1.1M
- Niraj DesaiMacon$129K
- Carlos MartinezMacon$126K
- Kimathi BlackwoodMacon$64K
- Reuben EllisMacon$27K
- Ahmad KabbaniMacon$16K
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.